Aveanna Healthcare (NASDAQ:AVAH) Price Target Raised to $13.00 at UBS Group

Aveanna Healthcare (NASDAQ:AVAH) had its price target raised by UBS Group from $8.00 to $13.00 in a research report sent to investors on Friday,Benzinga reports. UBS Group currently has a neutral rating on the stock.

Several other research firms have also issued reports on AVAH. Stephens raised Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $10.00 to $11.00 in a report on Friday, May 15th. Royal Bank Of Canada raised shares of Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a report on Wednesday, June 3rd. BMO Capital Markets raised their price target on Aveanna Healthcare from $10.00 to $14.00 and gave the company an “outperform” rating in a report on Friday. Raymond James Financial boosted their price objective on Aveanna Healthcare from $13.00 to $15.00 and gave the company a “strong-buy” rating in a research report on Friday. Finally, Truist Financial upped their price objective on Aveanna Healthcare from $9.00 to $11.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Aveanna Healthcare presently has an average rating of “Moderate Buy” and an average price target of $11.78.

Aveanna Healthcare Stock Performance

Shares of AVAH opened at $12.32 on Friday. The firm has a market capitalization of $2.68 billion, a P/E ratio of 10.02, a PEG ratio of 1.12 and a beta of 1.90. The company has a debt-to-equity ratio of 5.35, a current ratio of 1.47 and a quick ratio of 1.47. Aveanna Healthcare has a one year low of $5.93 and a one year high of $12.52. The business has a fifty day moving average of $8.97 and a 200 day moving average of $7.76.

Aveanna Healthcare (NASDAQ:AVAH) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.17 by $0.05. The company had revenue of $670.48 million for the quarter, compared to the consensus estimate of $638.61 million. Aveanna Healthcare had a net margin of 10.56% and a return on equity of 99.71%. As a group, sell-side analysts anticipate that Aveanna Healthcare will post 0.68 EPS for the current year.

Insider Buying and Selling at Aveanna Healthcare

In related news, insider Patrick A. Cunningham sold 125,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $7.59, for a total value of $948,750.00. Following the completion of the sale, the insider directly owned 212,755 shares in the company, valued at $1,614,810.45. This trade represents a 37.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Robert M. Williams, Jr. sold 7,000,000 shares of Aveanna Healthcare stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $6.24, for a total transaction of $43,680,000.00. Following the transaction, the insider directly owned 252,899 shares of the company’s stock, valued at $1,578,089.76. The trade was a 96.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 31,305,664 shares of company stock valued at $215,555,910. Corporate insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Aveanna Healthcare

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Aveanna Healthcare by 38.0% in the 4th quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock valued at $45,564,000 after acquiring an additional 1,535,351 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Aveanna Healthcare by 49.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,334,374 shares of the company’s stock worth $8,593,000 after purchasing an additional 441,707 shares during the period. Segall Bryant & Hamill LLC increased its holdings in Aveanna Healthcare by 425.8% in the 1st quarter. Segall Bryant & Hamill LLC now owns 163,966 shares of the company’s stock worth $1,056,000 after buying an additional 132,779 shares during the period. Weiss Asset Management LP purchased a new position in shares of Aveanna Healthcare during the first quarter worth $732,000. Finally, Smith Group Asset Management LLC raised its position in Aveanna Healthcare by 34.3% during the first quarter. Smith Group Asset Management LLC now owns 263,669 shares of the company’s stock valued at $1,698,000 after acquiring an additional 67,393 shares in the last quarter. Institutional investors own 87.96% of the company’s stock.

More Aveanna Healthcare News

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Q2 results exceeded expectations. Revenue increased 13.7% year over year to $670.5 million, while net income rose to $40.3 million from $27.0 million. Adjusted EBITDA reached $95.4 million, up 8.0%, and adjusted EPS of $0.22 topped analyst estimates of $0.19. Aveanna Healthcare Second Quarter Financial Results and Revised 2026 Guidance
• Positive Sentiment: Management raised full-year guidance. Aveanna now expects 2026 revenue above $2.68 billion, compared with its previous $2.63 billion-$2.65 billion range, and adjusted EBITDA above $365 million, up from $338 million-$342 million. The company cited reimbursement improvements, preferred-payer relationships and continued demand for complex home care. AVAH Q2 Earnings Call Highlights Higher Growth Targets
• Positive Sentiment: Analysts lifted their price targets. BMO Capital Markets raised its target from $10 to $14 and maintained an “outperform” rating. UBS raised its target from $8 to $13, although it retained a “neutral” rating. The revisions signal improved earnings expectations and support the stock’s recent strength. Benzinga analyst price target updates
• Neutral Sentiment: Growth is concentrated in Private Duty Services, which generates roughly 83% of revenue. Rapid revenue expansion is offsetting pressure on gross margins across business segments, making margin trends an important focus for investors. Aveanna Healthcare Q2 Earnings Report

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.